» Articles » PMID: 22226965

O-GlcNAc Modification of PPARγ Reduces Its Transcriptional Activity

Overview
Publisher Elsevier
Specialty Biochemistry
Date 2012 Jan 10
PMID 22226965
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

The peroxisome proliferator-activated receptor γ (PPARγ), a member of the nuclear receptor superfamily, is a key regulator of adipogenesis and is important for the homeostasis of the adipose tissue. The β-O-linked N-acetylglucosamine (O-GlcNAc) modification, a posttranslational modification on various nuclear and cytoplasmic proteins, is involved in the regulation of protein function. Here, we report that PPARγ is modified by O-GlcNAc in 3T3-L1 adipocytes. Mass spectrometric analysis and mutant studies revealed that the threonine 54 of the N-terminal AF-1 domain of PPARγ is the major O-GlcNAc site. Transcriptional activity of wild type PPARγ was decreased 30% by treatment with the specific O-GlcNAcase (OGA) inhibitor, but the T54A mutant of PPARγ did not respond to inhibitor treatment. In 3T3-L1 cells, an increase in O-GlcNAc modification by OGA inhibitor reduced PPARγ transcriptional activity and terminal adipocyte differentiation. Our results suggest that the O-GlcNAc state of PPARγ influences its transcriptional activity and is involved in adipocyte differentiation.

Citing Articles

O-GlcNAcylation: Sagacious Orchestrator of Bone-, Joint-, and Spine-Related Diseases.

Wei G, Jia H, Zhang Z, Qin J, Ao J, Qian H J Proteome Res. 2025; 24(3):981-994.

PMID: 39921656 PMC: 11894655. DOI: 10.1021/acs.jproteome.4c00859.


The Versatile Role of Peroxisome Proliferator-Activated Receptors in Immune-Mediated Intestinal Diseases.

Posta E, Fekete I, Varkonyi I, Zold E, Barta Z Cells. 2024; 13(20.

PMID: 39451206 PMC: 11505700. DOI: 10.3390/cells13201688.


Analysis of an adult diabetes mellitus caused by a rare mutation of the gene: A case report.

Li W, Xu L, Liu C, Dong B, Wang Y World J Clin Cases. 2024; 12(19):3942-3949.

PMID: 38994305 PMC: 11235441. DOI: 10.12998/wjcc.v12.i19.3942.


O-GlcNAcylation in ischemic diseases.

Shi R, He T, Lin M, Xu J, Gu J, Xu H Front Pharmacol. 2024; 15:1377235.

PMID: 38783961 PMC: 11113977. DOI: 10.3389/fphar.2024.1377235.


O-GlcNAcylation: cellular physiology and therapeutic target for human diseases.

Ye L, Ding W, Xiao D, Jia Y, Zhao Z, Ao X MedComm (2020). 2023; 4(6):e456.

PMID: 38116061 PMC: 10728774. DOI: 10.1002/mco2.456.